UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended November 30, 2014

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 333-173456

 

Jiu Feng Investment Hong Kong Ltd

(Exact name of registrant as specified in its charter)

 

Nevada

(State or other jurisdiction of incorporation or organization) 

 

2293 Hong Qiao Rd., Shanghai, China 200336

(Address of principal executive offices, including zip code)

 

+ 86 21 64748888

(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-Y (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

 

As of January 9, 2015, there are 8,500,000 shares of common stock outstanding.

 

All references in this Report on Form 10-Q to the terms “we”, “our”, “us”, the “Company”, “Jiu Feng” and the “Registrant” refer to Jiu Feng Investment Hong Kong Ltd unless the context indicates another meaning.

 

 

 

 

 

JIU FENG INVESTMENT HONG KONG LTD

 

TABLE OF CONTENTS

 

			Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements			3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations			4
Item 3.	Quantitative and Qualitative Disclosures About Market Risk			8
Item 4.	Controls and Procedures			8
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings			9
Item 1A.	Risk Factors			9
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds			9
Item 3.	Defaults Upon Senior Securities			9
Item 4.	Mine Safety Disclosures			9
Item 5.	Other Information			9
Item 6.	Exhibits			10
SIGNATURES				11

 

2

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

JIU FENG INVESTMENT HONG KONG LTD

 

FOR THE THREE AND NINE MONTH PERIODS ENDED NOVEMBER 30, 2014 AND 2013

 

Index to Condensed Unaudited Financial Statements

 

Contents		Page (s)
Condensed Balance Sheets at November 30, 2014 (Unaudited) and February 28, 2014 (Audited)		F-1
Condensed Statements of Operations for the Three and Nine Month Periods Ended November 30, 2014 and 2013 (Unaudited)		F-2
Condensed Statements of Cash Flows for the Nine Month Periods Ended November 30, 2014 and 2013 (Unaudited)		F-3
Notes to the Condensed Financial Statements (Unaudited)		F-4

 

3

 

Jiu Feng Investment Hong Kong Ltd

Condensed Balance Sheets

 

			November 30,				February 28,
			2014				2014
			(Unaudited)				(Audited)
ASSETS
	Current assets
	Cash		$	4,988			$	4,986
	Total current assets			4,988				4,986
	Other assets
	Deferred financing costs			30,000				30,000
	Total Assets		$	34,988			$	34,986
LIABILITIES & STOCKHOLDERS' DEFICIT
	Current liabilities
	Accounts payable and accrued liabilities		$	-			$	1,461
	Accrued officer compensation			312,000			$	195,000
	Loan payable - related party			138,376				93,607
	Total current liabilties			450,376				290,068
	Total Liabilities			450,376				290,068
	Stockholders' Deficit
	Common stock, $0.001 par value per share 75,000,000 shares authorized; 8,500,000 shares issued and outstanding			8,500				8,500
	Additional paid in capital			398,486				398,486
	Retained deficit			(822,374	)			(662,068	)
	Total Stockholders' Deficit			(415,388	)			(255,082	)
	Total Liabilities and Stockholders' Deficit		$	34,988			$	34,986

 

The accompanying notes are an integral part of these condensed unuadited financial statements. 

 

F-1

 

JIU FENG INVESTMENT HONG KONG LTD.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

		Three Months				Three Months				Nine Months				Nine Months
		Ended				Ended				Ended				Ended
		November 30, 2014				November 30, 2013				November 30, 2014				November 30, 2013
Revenue		$	-			$	-			$	-			$	-
Operating Expenses:
General and administrative			49,921				20,035				160,308				62,940
Total operating expenses			49,921				20,035				160,308				62,940
Income (loss) from operations			(49,921	)			(20,035	)			(160,308	)			(62,940	)
Other income (expense):
Interest income			-				-				2				-
Other income (expense) net			-				-				2				-
Income (loss) before provision for income taxes			(49,921	)			(20,035	)			(160,306	)			(62,940	)
Provision for income tax:			-				-				-				-
Net income (loss)		$	(49,921	)		$	(20,035	)		$	(160,306	)		$	(62,940	)
Net income (loss) per share:
(Basic and fully diluted)		$	(0.01	)		$	(0.00	)	*	$	(0.02	)		$	(0.01	)
Weighted average number of common shares outstanding:
(Basic and fully diluted)			8,500,000				6,500,000				8,500,000				6,500,000

 

 * denotes a loss of less than $(0.01) per share

 

The accompanying notes are an integral part of these condensed unuadited financial statements. 

 

F-2

 

JIU FENG INVESTMENT HONG KONG LTD.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

			Nine Months				Nine Months
			Ended				Ended
			November 30,				November 30,
			2014				2013
Cash Flows From Operating Activities:
	Net income (loss)		$	(160,306	)		$	(62,940	)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
	Changes in Current Assets and Liabilities:
	Accounts payable			(1,461	)			-
	Accrued officer compensation			117,000				-
	Net cash provided by (used for) operating activities			(44,767	)			(62,940	)
Cash Flows From Investing Activities:
				-				-
	Net cash provided by (used for) investing activities			-				-
Cash Flows From Financing Activities:
	Loan - related party			44,769				62,926
	Net cash provided by (used for) financing activities			44,769				62,926
Net Increase (Decrease) In Cash				2				(14	)
Cash At The Beginning Of The Period				4,986				5,000
Cash At The End Of The Period			$	4,988			$	4,986
Schedule of Non-Cash Investing and Financing Activities
			None.
Supplemental Discloures
Cash paid for interest			$	-			$	-
Cash paid for income taxes			$	-			$	-

 

The accompanying notes are an integral part of these condensed unuadited financial statements. 

 

F-3

 

JIU FENG INVESTMENT HONG KONG LTD. 

NOTES TO CONDENSED FINANCIAL STATEMENTS 

FOR THE THREE AND NINE MONTHS ENDED NOVEMBER 30, 2014 AND 2013 

(Unaudited)

 

NOTE 1 – ORGANIZATION AND OPERATIONS

 

Jiu Feng Investment Hong Kong, Inc., (the “Company”) was formed on September 29, 2009 under the name Liberty Vision, Inc. The Company provided web development and marketing services for clients. On December 5, 2012 the Company disposed of its subsidiary corporation to a shareholder for a nominal sum, as well as other management operations. On December 16, 2012, the Company changed its name to Jiu Feng Investment Hong Kong, Inc. On July 24, 2013, the Company changed its business sector to the medical sector. On September 30, 2013, the Company entered into a world-wide five year licensing agreement with BioMark Technologies (Asia) Limited ("BioMark") whereby the Company is licensed to sell, market, and, or, distribute certain products pertaining to the health care industry; and to conduct research and development of BioMark’s cancer detection scanning technology.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.GAAP”).

 

Unaudited Interim Financial Statements

 

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

 

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

 

F-4

  

Use of estimates and assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

 

The Company’s significant estimates include the valuation allowance of deferred tax assets; the fair value of financial instruments and the assumption that the company will continue as a going concern. Those significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to those estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.

 

Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

 

Fiscal year end

 

The Company elected February 28 as its fiscal year end date.

 

Cash and cash equivalents

 

The Company considers all highly liquid investments with a maturity of three months or less to be cash and cash equivalents.

 

Deferred Financing Costs

 

Costs with respect to issue of common stock, warrants, stock options or debt instruments by the Company are initially deferred and ultimately offset against the proceeds from such equity transactions or amortized as debt discount over the term of any debt funding if successful or expensed if the proposed equity or debt transaction is unsuccessful.

 

During the twelve months ended February 28, 2014, the Company paid cash in the amount of $5,000 and issued 500,000 shares of common stock valued at $25,000 as compensation for the preparation of a form S-1 to be filed during the year ended February 28, 2015.

 

As at November 30, 2014 and February 28, 2014 the balance of deferred financing cost totaled $30,000.

 

F-5

  

Fair value of financial instruments

 

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and has adopted paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 of the FASB Accounting Standards Codification establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, paragraph 820-1-35-37 of the FASB Accounting Standards Codification establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by paragraph 820-10-35-37 of the FASB Accounting Standards Codification are described below:

 

Level 1

Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

 

Level 2

Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

 

Level 3

Pricing inputs that are generally observable inputs and not corroborated by market data.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, deferred financing costs, accounts payable and accrued expenses and loan payable – related party approximate their fair values because of the short maturity of these instruments.

 

Carrying Value, Recoverability and Impairment of Long-Lived Assets

 

The Company has adopted paragraph 360-10-35-17 of the FASB Accounting Standards Codification for its long-lived assets. The Company’s long-lived assets, which include office equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset August not be recoverable.

 

The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.

 

F-6

  

The Company considers the following to be some examples of important indicators that August trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates acquired assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events.

 

The impairment charges, if any, are included in operating expense in the accompanying statements of income and comprehensive income (loss).

 

Commitments and contingencies

 

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

 

Revenue Recognition

 

The Company applies paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer; (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured.

 

Foreign currency transactions

 

The Company applies the guidelines as set out in Section 830-20-35 of the FASB Accounting Standards Codification (“Section 830-20-35”) for foreign currency transactions. Pursuant to Section 830-20-35 of the FASB Accounting Standards Codification, foreign currency transactions are transactions denominated in currencies other than the US Dollar, the Company’s reporting currency. Foreign currency transactions may produce receivables or payables that are fixed in terms of the amount of foreign currency that will be received or paid. A change in exchange rates between the reporting currency and the currency in which a transaction is denominated increases or decreases the expected amount of reporting currency cash flows is a foreign currency transaction gain or loss that generally shall be included in determining net income for the period in which the exchange rate changes. Likewise, a transaction gain or loss (measured from the transaction date or the most recent intervening balance sheet date, whichever is later) realized upon settlement of a foreign currency transaction generally shall be included in determining net income for the period in which the transaction is settled. The exceptions to this requirement for inclusion in net income of transaction gains and losses pertain to certain intercompany transactions and to transactions that are designated as, and effective as, economic hedges of net investments and foreign currency commitments. Pursuant to Section 830-20-25 of the FASB Accounting Standards Codification, the following shall apply to all foreign currency transactions of an enterprise and its investees: (a) at the date the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction shall be measured and recorded in the functional currency of the recording entity by use of the exchange are in effect at that date as defined in Section 830-10-20 of the FASB Accounting Standards Codification; and (b) at each balance sheet date, recorded balances that are denominated in currencies other than the functional currency or reporting currency of the recording entity shall be adjusted to reflect the current exchange rate.

 

F-7

  

All of the Company’s operations are carried out in U.S. Dollars. The Company uses the U.S. Dollar as its reporting currency as well as its functional currency.

 

Income taxes

 

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Net income (loss) per common share

 

Net income (loss) per common share is computed pursuant to section 2660-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. There were no potentially dilutive debt or equity instruments issued or outstanding during the three and nine months ended November 30, 2014 and 2013.

 

Advertising Costs

 

The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expense of $0 during three and nine months ended November 30, 2014 and 2013.

 

Recent accounting pronouncements

 

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements, and does not believe any of these pronouncements will have a material impact on the Company’s financial statements.

 

F-8

 

NOTE 3 – GOING CONCERN

 

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at November 30, 2014 the Company had current assets, comprising of cash, of $4,988 and current liabilities of $450,376 resulting in a working capital deficit of $445,388. The Company currently has no profitable trading activities and has an accumulated deficit of $822,374 as at November 30, 2014. This raises substantial doubt about the Company’s ability to continue as a going concern.

 

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its new business plan in the medical sector on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives.

 

NOTE 4 – ACCRUED OFFICER COMPENSATION

 

On April 17, 2013, the Company entered into Employment Agreements with its president, Ms. Yan Li, and its secretary and treasurer, Mr. Robert Ireland. Ms. Yan’s agreement is retroactively effective as of December 4, 2012, for a term of 36 months (measured from December 4, 2012). Pursuant to the agreement, Ms. Li shall receive an annual salary of $78,000, and shall act as the Company’s Chief Executive Officer. 

 

Mr. Ireland’s agreement is retroactively effective as of December 4, 2012, for a term of 36 months (measured from December 4, 2012). Pursuant to the agreement, Mr. Ireland shall receive an annual salary of $78,000, and shall act as the company’s Secretary and Treasurer.

 

As at November 30, 2014, a total of $312,000 had been accrued as compensation payable to Ms. Li and Mr. Ireland.

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note.

 

As of November 30, 2014, the Company had a $138,376 loan outstanding with a shareholder of the Company. The loan is non-interest bearing, due upon demand and unsecured.

 

F-9

 

NOTE 6 – COMMON STOCK 

 

The Company has 75,000,000 shares of common stock authorized with a par value of $ 0.001 per share.

 

On August 15, 2013 the Company issued 2,000,000 shares of its common stock to unrelated parties for services rendered. The share issuance was valued at $0.05 per common share. At close of business on August 15, 2013 the stock was quoted at a price of $1.46 per share, but as there was, and is, no active trading market, management does not believe that this is a true indication of the fair value of these shares. The value assigned is based on the price at which the Company had most recently sold shares of its common stock for cash.

 

Of the 2,000,000 shares issued, 1,500,000 of the shares issued in the year related to consulting services and the $75,000 cost associated with them expensed in the statement of operations. 500,000 of the shares issued in the year related to preparation of a form S1 and the $25,000 cost associated with them has been capitalized as deferred financing costs.

 

No shares of common stock were issued during the three and nine months ended November 30, 2014.

 

Total shares outstanding as of November 30, 2014 were 8,500,000.

 

NOTE 7 – INCOME TAX

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

 

At November 30, 2014, after the disposal of its subsidiary Company in fiscal 2013, the Company had net operating loss carryforwards of approximately $591,000 which begin to expire in 2034. The deferred tax asset of $201,000 created by the net operating loss has been offset by a 100% valuation allowance. The change in valuation allowance as of the quarter ended November 30, 2014 was approximately $17,000.

 

NOTE 8 – SUBSEQUENT EVENTS

 

In accordance with ASC 855-10, “Subsequent Events”, the Company has analyzed its operations subsequent to November 30, 2014 to the date these financial statements were filed with the Securities and Exchange Commission and has determined that it does not have any material subsequent events to disclose in these financial statements.

 

F-10

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. This Quarterly Report on Form 10-Q contains certain statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Certain statements contained in the MD&A are forward-looking statements that involve risks and uncertainties. The forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry, business and future financial results. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed in other sections of this Quarterly Report on Form 10-Q.

 

Our Business

 

Jiu Feng Investment Hong Kong, Ltd., (the “Company”, “the “Registrant”, “we”, “us” or “our”) was formed on September 29, 2009 under the name Liberty Vision, Inc.  The Company provided web development and marketing services for clients. On December 5, 2012 the Company disposed of its subsidiary corporation to a shareholder for a nominal sum, as well as other management operations. On December 16, 2012, the Company changed its name to Jiu Feng Investment Hong Kong, Inc. On January 27, 2013, the Company announced the change of their ticker symbol from “LBYV” to “JFIL.” On July 24, 2013, the Company changed its business sector to the medical sector. On September 30, 2013, the Company entered into a world-wide five year licensing agreement with BioMark Technologies (Asia) Limited ("BioMark") whereby the Company is licensed to sell, market, and, or, distribute certain products pertaining to the health care industry; and to conduct research and development of BioMark’s cancer detection scanning technology. 

 

The Company develops and plans to market medical products under license from BioMark. The licensed products include Bone-Induction Artificial Bone (BIAB) products and Vacuum Sealing Drainage (VSD) products. The Company is also licensed to conduct research and development of BioMark’s cancer detection scanning technology. In the event that the research and development of BioMark’s cancer detection scanning technology provides marketable technology, the Company shall have the right of first refusal to a license to market, sell and distribute such cancer detection scanning technology.

 

Results of Operations

 

For the three months ended November 30, 2014 compared to the three months ended November 30, 2013

 

Revenue 

 

We recognized no revenue in the three months ended November 30, 2014 and 2013 as we have not commenced operations as yet.

 

Operating Expenses 

 

The major components of our operating expenses for the three months ended November 30, 2014 and 2013 are outlined in the table below:

 

		Three Months Ended November 30, 2014				Three Months Ended November 30, 2013				Increase (Decrease) %
Professional fees		$	8,445			$	2,606				224.06	%
Officer compensation			39,000				0				100	%
Consulting			0				16,074				(100	%)
Other			2,476				1,355				82.73	%
Total operating expenses		$	49,921			$	20,035				149.17	%

 

4

 

During the three months ended November 30, 2014, we accrued $39,000 in officer compensation while during the three months ended November 30, 2013 we made no accrual for officer compensation. We incurred $8,445 in professional fees for the period ended November 30, 2014 compared to $2,606 for the same period in fiscal 2013. During the three months ended November 30, 2014 we incurred no consulting fees compared to $16,074 in the three months ended November 30, 2013. Other expenses such as Edgar agent fees and other filing fees were $2,476 for the three months ended November 30, 2014 and $1,355 for the three months ended November 30, 2013. These increases in our operating costs for the three months ended November 30, 2014, compared to the same period in our fiscal 2013, were due to the accelerated implementation of our business plan in the three months ended November 30, 2014 as compared to the three months ended November 30, 2013.

 

Net Loss

 

For the three months ended November 30, 2014, we recognized a net loss of $49,921 compared to a net loss of $20,035 for the corresponding period in 2013 due to the factors discussed above.

 

For the nine months ended November 30, 2014 compared to the nine months ended November 30, 2013

 

Revenue 

 

We recognized no revenue in the nine months ended November 30, 2014 and 2013 as we have not commenced operations as yet.

 

Operating Expenses 

 

The major components of our operating expenses for the nine months ended November 30, 2014 and 2013 are outlined in the table below:

 

		Nine Months Ended November 30, 2014				Nine Months Ended November 30, 2013				Increase (Decrease) %
Professional fees		$	33,957			$	21,017				61.57	%
Officer compensation			117,000				0				100.00	%
Consulting			0				37,404				(100.00	%)
Other			9,351				4,519				106.93	%
Total operating expenses		$	160,308			$	62,940				154.70	%

 

5

 

During the nine months ended November 30, 2014, we accrued $117,000 in officer compensation while during the nine months ended November 30, 2013 we made no accrual for officer compensation. We incurred $33,957 in professional fees for nine months ended November 30, 2014 compared to $21,017 for the same period in fiscal 2013. During the nine months ended November 30, 2014 we incurred no consulting fees compared to $37,404 in the nine months ended November 30, 2013. Other expenses such as Edgar agent fees and other filing fees were $9,351 for the nine months ended November 30, 2014 and $34,519 for the nine months ended November 30, 2013. These increases in our operating costs for the nine months ended November 30, 2014, compared to the same period in our fiscal 2013, were due to the accelerated implementation of our business plan in the nine months ended November 30, 2014 as compared to the nine months ended November 30, 2013.

 

Net Loss

 

For the nine months ended November 30, 2014, we recognized a net loss of $160,306 compared to a net loss of $62,940 for the corresponding period in 2013 due to the factors discussed above.

 

Liquidity and Capital Resources

 

Working Capital

 

		November 30, 2014				February 28, 2014
Current Assets		$	4,988			$	4,986
Current Liabilities		$	450,376			$	290,068
Working Capital Deficit		$	(445,388	)		$	(285,082	)

 

As at November 30, 2014 the Company had current assets, comprising of cash, of $4,988 and current liabilities of $450,376 resulting in a working capital deficit of $445,388. The Company currently has no profitable trading activities and has an accumulated deficit of $822,374 as at November 30, 2014. This raises substantial doubt about the Company’s ability to continue as a going concern.

 

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future

 

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its new business plan in the medical sector on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives.

 

6

 

Cash Flow for the nine months ended November 30, 2014 compared to the nine months ended November 30, 2013

 

The table below, for the periods indicated, provides selected cash flow information:

 

		Nine months Ended November 30, 2014				Nine Months Ended November 30, 2013
Cash provided by (used in) operating activities		$	(44,767	)		$	(62,940	)
Cash used in investing activities			0				0
Cash provided by financing activities			44,769				62,926
Net increase (decrease) in cash		$	2			$	(14	)

 

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its new business plan in the medical sector on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives.

Cash Flows from Operating Activities

 

Our net cash used in operating activities decreased by $18,173 in the nine months ended November 30, 2014 compared to that in the nine months ended November 30, 2013, representing a decrease of 28.87%. The decrease in net cash used in operating activities was primarily the result of the increase in our net loss from $62,940 in the nine months ended November 30, 2013 to $160,306 during the nine months ended November 30, 2014, increased for cash flow purposes by a reduction of $1,461 in our balance of accounts payable during the nine months ended November 30, 2014 and reduced for cash flow purposes by a $117,000 increase in our balance of accrued officer compensation during the nine months ended November 30, 2014.

 

Cash Flows from Investing Activities 

 

We did not generate or use any cash from investing activities during the nine months ended November 30, 2014 and 2013.

 

Cash Flows from Financing Activities 

 

Our cash provided by financing activities decreased from $62,926 for the nine months ended November 30, 2013 to $44,767 for the nine months ended November 30, 2014. In both periods, cash was provided by way of loan from related party.

 

7

 

Future Financings

 

We anticipate that additional funding will be required in the form of equity financing from the sale of our common stock, through an offering of debt securities, or through borrowings from financial institutions or related parties. However, we cannot provide investors with any assurance that we will be able to raise sufficient funding from the sale of our common stock or through a loan from our directors to meet our obligations over the next twelve months. We do not have any arrangements in place for any future equity financing.

 

Recent Accounting Pronouncements 

 

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements, and does not believe any of these pronouncements will have a material impact on the Company’s financial statements.

 

Off Balance Sheet Arrangements

 

As of November 30, 2014, we did not have any off-balance-sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. 

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were effective such that the material information required to be included in our Securities and Exchange Commission reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating to our company, particularly during the period when this report was being prepared.

 

Additionally, there were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the evaluation date. We have not identified any significant deficiencies or material weaknesses in our internal controls, and therefore there were no corrective actions taken.

 

8

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

We were not subject to any legal proceedings during the three and nine months ended November 30, 2014 and 2013 and currently we are not involved in any pending litigation or legal proceedings.

 

ITEM 1A. RISK FACTORS.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

 No unregistered sales of equity were completed in the three and nine months ended November 30, 2014 or 2013.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

No senior securities were issued and outstanding during the three and nine months ended November 30, 2014 or 2013.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable to our Company.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

9

 

ITEM 6. EXHIBITS 

The following documents are filed as a part of this report:

 

EXHIBIT NUMBER		DESCRIPTION
31.1		Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS **		XBRL Instance Document
101.SCH **		XBRL Taxonomy Extension Schema Document
101.CAL **		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF **		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB **		XBRL Taxonomy Extension Label Linkbase Document
101.PRE **		XBRL Taxonomy Extension Presentation Linkbase Document

_____________

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

10

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

 

	JIU FENG INVESTMENT HONG KONG LTD
Date: January 13, 2015	By:	/s/ Yan Li
		Yan Li,
		President and Director

 

 

11

---